Search

Your search keyword '"Wojdyla, Daniel"' showing total 662 results
Start Over Author "Wojdyla, Daniel" Publication Type Academic Journals
662 results on '"Wojdyla, Daniel"'

1. A Comparative Analysis of Health-Related Quality of Life 1 Year Following Myomectomy or Uterine Artery Embolization: Findings from the COMPARE-UF Registry.

Author

Anchan, Raymond, Wojdyla, Daniel, Bortoletto, Pietro, Terry, Kathryn, Disler, Emily, Milne, Ankrish, Gargiulo, Antonio, Petrozza, John, Brook, Olga, Srouji, Serene, Morton, Cynthia, Greenberg, James, Wegienka, Ganesa, Stewart, Elizabeth, Nicholson, Wanda, Thomas, Laine, Venable, Sateria, Laughlin-Tommaso, Shannon, Diamond, Michael, Maxwell, G, Marsh, Erica, Myers, Evan, Vines, Anissa, Wise, Lauren, Wallace, Kedra, Spies, James, and Jacoby, Vanessa

Subjects
hysterectomy, myomectomy, quality of life, uterine artery embolization, uterine fibroids, Female, Humans, Hysterectomy, Leiomyoma, Prospective Studies, Quality of Life, Registries, Treatment Outcome, Uterine Artery Embolization, Uterine Myomectomy, Uterine Neoplasms
Abstract

Objective: To compare 12-month post-treatment health-related quality of life (HR-QoL) and symptom severity (SS) changes among patients with symptomatic uterine fibroids (SUF) not seeking fertility and undergo a hysterectomy, abdominal myomectomy (AM), or uterine artery embolization (UAE). Materials and Methods: The Comparing Options for Management: Patient-Centered Results for Uterine Fibroids (COMPARE-UF) Registry is a multi-institutional prospective observational cohort study of patients treated for SUF. A subset of 1465 women 31-45 years of age, who underwent either hysterectomy (n = 741), AM (n = 446), or UAE (n = 155) were included in this analysis. Demographics, fibroid history, and symptoms were obtained by baseline questionnaires and at 1 year post-treatment. Results were stratified by all treatments and propensity score weighting to adjust for differences in baseline characteristics. Results: Women undergoing UAE reported the lowest baseline HR-QoL and highest SS scores (mean = 40.6 [standard deviation (SD) = 23.8]; 62.3 [SD = 24.2]) followed by hysterectomy (44.3 [24.3]; 59.8 [SD = 24.1]). At 12 months, women who underwent a hysterectomy experienced the largest change in both HR-QoL (48.7 [26.2]) and SS (51.9 [25.6]) followed by other uterine-sparing treatments. Propensity score weighting revealed all treatments produced substantial improvement, with hysterectomy patients reporting the highest HR-QoL score (92.0 [17.8]) compared with myomectomy (86.7 [17.2]) and UAE (82.6 [21.5]) (p

Published
2023

2. Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation: Insights From ARTESiA

Author

Lopes, Renato D., Granger, Christopher B., Wojdyla, Daniel M., McIntyre, William F., Alings, Marco, Mani, Thenmozhi, Ramasundarahettige, Chinthanie, Rivard, Lena, Atar, Dan, Birnie, David H., Boriani, Giuseppe, Amit, Guy, Leong-Sit, Peter, Rinne, Claus, Duray, Gabor Z., Gold, Michael R., Hohnloser, Stefan H., Kutyifa, Valentina, Benezet-Mazuecos, Juan, Cosedis Nielsen, Jens, Sticherling, Christian, Benz, Alexander P., Linde, Cecilia, Kautzner, Joseph, Mabo, Philippe, Mairesse, Georges H., Connolly, Stuart J., and Healey, Jeff S.

Published
2024
Full Text
View/download PDF

17. Graft Failure After Coronary Artery Bypass Grafting and Its Association With Patient Characteristics and Clinical Events: A Pooled Individual Patient Data Analysis of Clinical Trials With Imaging Follow-Up

Author

Gaudino, Mario, Sandner, Sigrid, An, Kevin R., Dimagli, Arnaldo, Di Franco, Antonino, Audisio, Katia, Harik, Lamia, Perezgrovas-Olaria, Roberto, Soletti, Giovanni, Fremes, Stephen E., Hare, David L., Kulik, Alexander, Lamy, Andre, Peper, Joyce, Ruel, Marc, ten Berg, Jurrien M., Willemsen, Laura M., Zhao, Qiang, Wojdyla, Daniel M., Bhatt, Deepak L., Alexander, John H., and Redfors, Bjorn

Published
2023
Full Text
View/download PDF

19. Antithrombotic Strategies in Atrial Fibrillation After ACS and/or PCI: A 4-Way Comparison From AUGUSTUS.

Author

Berwanger, Otavio, Wojdyla, Daniel M., Fanaroff, Alexander C., Budaj, Andrzej, Granger, Christopher B., Mehran, Roxana, Aronson, Ronald, Windecker, Stephan, Goodman, Shaun G., Alexander, John H., and Lopes, Renato D.

Subjects
*ACUTE coronary syndrome, *ANTICOAGULANTS, *PERCUTANEOUS coronary intervention, *ATRIAL fibrillation, *FACTORIAL experiment designs
Abstract

The optimal antithrombotic regimen for patients with atrial fibrillation (AF) who had an acute coronary syndrome (ACS) or have undergone percutaneous coronary intervention (PCI) is not known. The authors sought to determine which antithrombotic regimen best balances safety and efficacy. AUGUSTUS, a multicenter 2 × 2 factorial design randomized trial compared apixaban with vitamin K antagonist (VKA) and aspirin with placebo in patients with AF with recent ACS and/or PCI treated with a P2Y 12 inhibitor. We conducted a 4-way analysis comparing safety and efficacy outcomes in the 4 randomized groups. The primary outcome was a composite of all-cause death, major or clinically relevant nonmajor bleeding, or hospitalization for cardiovascular causes over 6-month follow-up. Secondary outcomes included individual components of the primary endpoint. A total of 4,614 patients were enrolled. All patients were treated with a P2Y 12 inhibitor. The primary endpoint occurred in 21.9% of patients randomized to apixaban plus placebo, 27.3% randomized to apixaban plus aspirin, 28.0% randomized to VKA plus placebo, and 33.3% randomized to VKA plus aspirin. Rates of major or clinically relevant nonmajor bleeding and hospitalization for cardiovascular causes were lower with apixaban and placebo compared with the other 3 antithrombotic strategies. There was no difference between the 4 randomized groups with respect to all-cause death. In patients with AF and a recent ACS and/or PCI, an antithrombotic regimen that included a P2Y 12 inhibitor and apixaban without aspirin resulted in a lower incidence of the composite of death, bleeding, or cardiovascular hospitalization than regimens including VKA, aspirin, or both. (An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Intervention; NCT02415400) [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. On‐treatment analysis of torsemide versus furosemide for patients hospitalized for heart failure: A post‐hoc analysis of TRANSFORM‐HF.

Author

Kittipibul, Veraprapas, Mentz, Robert J., Clare, Robert M., Wojdyla, Daniel M., Anstrom, Kevin J., Eisenstein, Eric L., Ambrosy, Andrew P., Goyal, Parag, Skopicki, Hal A., Ketema, Fassil, Kim, Dong‐Yun, Desvigne‐Nickens, Patrice, Pitt, Bertram, Velazquez, Eric J., and Greene, Stephen J.

Subjects
HEART failure patients, FAILURE analysis, FUROSEMIDE, MORTALITY, HOSPITAL admission & discharge
Abstract

Aim: The TRANSFORM‐HF trial demonstrated no significant outcome differences between torsemide and furosemide following hospitalization for heart failure (HF), but may have been impacted by non‐adherence to the randomized diuretic. The current study sought to determine the treatment effect of torsemide versus furosemide using an on‐treatment analysis inclusive of all randomized patients except those confirmed non‐adherent to study diuretic. Methods and results: TRANSFORM‐HF was an open‐label, pragmatic randomized trial of 2859 patients hospitalized for HF from June 2018 through March 2022. Patients were randomized to a loop diuretic strategy of torsemide versus furosemide with investigator‐selected dosage. This post‐hoc on‐treatment analysis included all patients alive with either known or unknown diuretic status, and excluded patients confirmed to be non‐adherent to study diuretic. This modified on‐treatment definition was applied separately at time of hospital discharge and 30‐day follow‐up. All‐cause mortality and hospitalization outcomes were assessed over 12 months. Overall, 2570 (89.9%) and 2374 (83.0%) patients were included in on‐treatment analyses at discharge and 30‐day follow‐up, respectively. There was no significant difference in all‐cause mortality between torsemide and furosemide in patients on‐treatment at discharge (17.5% vs. 17.8%; hazard ratio [HR] 1.01 [95% confidence interval [CI] 0.83–1.22], p = 0.96) and at 30‐day follow‐up (14.5% vs. 15.0%; HR 1.02 [95% CI 0.81–1.27], p = 0.90). All‐cause mortality or all‐cause hospitalization was similar between torsemide and furosemide in patients who were on‐treatment at discharge (58.3% vs. 61.3%; HR 0.92 [95% CI 0.82–1.03]) and 30‐day follow‐up (60.9% vs. 64.4%; HR 0.93 [95% CI 0.82–1.05]). In patients who were on‐treatment at 30‐day follow‐up, there were 677 total hospitalizations in the torsemide group and 686 total hospitalizations in the furosemide group (rate ratio 0.99 [95% CI 0.86–1.14], p = 0.87). Conclusions: In TRANSFORM‐HF, a post‐hoc on‐treatment analysis did not meaningfully differ from the original trial results. Among those deemed compliant with the assigned diuretic, there remained no significant difference in mortality or hospitalization after HF hospitalization with a strategy of torsemide versus furosemide. Clinical Trail Registration: ClinicalTrials.gov Identifier: NCT03296813. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

24. Long-term health-related quality of life and symptom severity following hysterectomy, myomectomy, or uterine artery embolization for the treatment of symptomatic uterine fibroids

Author

Anchan, Raymond M., Spies, James B., Zhang, Shuaiqi, Wojdyla, Daniel, Bortoletto, Pietro, Terry, Kathryn, Disler, Emily, Milne, Ankrish, Gargiulo, Antonio, Petrozza, John, Brook, Olga, Srouji, Serene, Morton, Cynthia C., Greenberg, James, Wegienka, Ganesa, Stewart, Elizabeth A., Nicholson, Wanda K., Thomas, Laine, Venable, Sateria, Laughlin-Tommaso, Shannon, Diamond, Michael P., Maxwell, G. Larry, Marsh, Erica E., Myers, Evan R., Vines, Anissa I., Wise, Lauren A., Wallace, Kedra, and Jacoby, Vanessa L.

Published
2023
Full Text
View/download PDF

26. Impact of baseline kidney dysfunction on oral diuretic efficacy following hospitalization for heart failure – insights from TRANSFORM‐HF.

Author

Martens, Pieter, Greene, Stephen J., Mentz, Robert J., Li, Shuang, Wojdyla, Daniel, Kapelios, Chris J., Mullens, Wilfried, Hall, Michael E., Ketema, Fassil, Kim, Dong‐Yun, Eisenstein, Eric L., Anstrom, Kevin, Fang, James C., Pitt, Bertram, Velazquez, Eric J., and Tang, W.H. Wilson

Subjects
HEART failure, GLOMERULAR filtration rate, HOSPITAL care, DIURETICS, KIDNEY physiology
Abstract

Aim: Among patients discharged after hospitalization for heart failure (HF), a strategy of torsemide versus furosemide showed no difference in all‐cause mortality or hospitalization. Clinicians have traditionally favoured torsemide in the setting of kidney dysfunction due to better oral bioavailability and longer half‐life, but direct supportive evidence is lacking. Methods and results: The TRANSFORM‐HF trial randomized patients hospitalized for HF to a long‐term strategy of torsemide versus furosemide, and enrolled patients across the spectrum of renal function (without dialysis). In this post‐hoc analysis, baseline renal function during the index hospitalization was assessed as categories of estimated glomerular filtration rate (eGFR; <30, 30–<60, ≥60 ml/min/1.73 m2). The interaction between baseline renal function and treatment effect of torsemide versus furosemide was assessed with respect to mortality and hospitalization outcomes, and the change in Kansas City Cardiomyopathy Questionnaire clinical summary score (KCCQ‐CSS). Of 2859 patients randomized, 336 (11.8%) had eGFR <30 ml/min/1.73 m2, 1138 (39.8%) had eGFR 30–<60 ml/min/1.73 m2, and 1385 (48.4%) had eGFR ≥60 ml/min/1.73 m2. Baseline eGFR did not modify treatment effects of torsemide versus furosemide on all adverse clinical outcomes including individual components or composites of all‐cause mortality and all‐cause (re)‐hospitalizations, both when assessing eGFR categorically or continuously (p‐value for interaction all >0.108). Similarly, no treatment effect modification by eGFR was found for the change in KCCQ‐CSS (p‐value for interaction all >0.052) when assessing eGFR categorically or continuously. Conclusion: Among patients discharged after hospitalization for HF, there was no significant difference in clinical and patient‐reported outcomes between torsemide and furosemide, irrespective of renal function. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex

Author

Carnicelli, Anthony P., Hong, Hwanhee, Connolly, Stuart J., Eikelboom, John, Giugliano, Robert P., Morrow, David A., Patel, Manesh R., Wallentin, Lars, Alexander, John H., Cecilia Bahit, M., Benz, Alexander P., Bohula, Erin A., Chao, Tze-Fan, Dyal, Leanne, Ezekowitz, Michael, A.A. Fox, Keith, Gencer, Baris, Halperin, Jonathan L., Hijazi, Ziad, Hohnloser, Stefan H., Hua, Kaiyuan, Hylek, Elaine, Toda Kato, Eri, Kuder, Julia, Lopes, Renato D., Mahaffey, Kenneth W., Oldgren, Jonas, Piccini, Jonathan P., Ruff, Christian T., Steffel, Jan, Wojdyla, Daniel, and Granger, Christopher B.

Published
2022
Full Text
View/download PDF

37. Apixaban or Vitamin K Antagonists and Aspirin or Placebo According to Kidney Function in Patients with Atrial Fibrillation After Acute Coronary Syndrome or PCI: Insights from The AUGUSTUS Trial

Author

Hijazi, Ziad, Alexander, John H., Li, Zhuokai, Wojdyla, Daniel M., Mehran, Roxana, Granger, Christopher B., Parkhomenko, Alexander, Bahit, M. Cecilia, Windecker, Stephan, Aronson, Ronald, Berwanger, Otavio, Halvorsen, Sigrun, de Waha-Thiele, Suzanne, Sinnaeve, Peter, Darius, Harald, Storey, Robert F., and Lopes, Renato D.

Published
2021
Full Text
View/download PDF

41. Digoxin and Mortality in Patients With Atrial Fibrillation

Author

Lopes, Renato D., Rordorf, Roberto, De Ferrari, Gaetano M., Leonardi, Sergio, Thomas, Laine, Wojdyla, Daniel M., Ridefelt, Peter, Lawrence, John H., De Caterina, Raffaele, Vinereanu, Dragos, Hanna, Michael, Flaker, Greg, Al-Khatib, Sana M., Hohnloser, Stefan H., Alexander, John H., Granger, Christopher B., and Wallentin, Lars

Published
2018
Full Text
View/download PDF

47. Abstract 15664: Prior Oral Anticoagulant Status and Outcomes in Patients With Atrial Fibrillation With an Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From the Augustus Trial

Author

Welsh, Robert C, Lopes, Renato D, Wojdyla, Daniel, Aronson, Ronald, Granger, Christopher B, Windecker, Stephan, Vora, Amit, Vinereanu, Dragos, Halvorsen, Sigrun, Parkhomenko, Alexander, Mehran, Roxana, Alexander, John H, and Goodman, Shaun G

Published
2020
Full Text
View/download PDF

50. Differential Treatments Based on Drug-induced Gene Expression Signatures and Longitudinal Systemic Lupus Erythematosus Stratification

Author

Toro-Domínguez, Daniel, Lopez-Domínguez, Raúl, García Moreno, Adrián, Villatoro-García, Juan A., Martorell-Marugán, Jordi, Goldman, Daniel, Petri, Michelle, Wojdyla, Daniel, Pons-Estel, Bernardo A., Isenberg, David, Morales-Montes de Oca, Gabriela, Trejo-Zambrano, María Isabel, García González, Benjamín, Rosetti, Florencia, Gómez-Martín, Diana, Romero-Díaz, Juanita, Carmona-Sáez, Pedro, and Alarcón-Riquelme, Marta E.

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results